Hassan Bousbaa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4314082/publications.pdf

Version: 2024-02-01

58 papers	1,956 citations	23 h-index	254184 43 g-index
58	58	58	2436
all docs	docs citations	times ranked	citing authors

#	Article	lF	Citations
1	Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research. Pharmaceutics, 2020, 12, 1186.	4.5	185
2	Mutations in the Essential Spindle Checkpoint Gene bub1 Cause Chromosome Missegregation and Fail to Block Apoptosis in Drosophila. Journal of Cell Biology, 1999, 146, 13-28.	5.2	184
3	Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats Journal of Clinical Investigation, 1994, 94, 578-584.	8.2	117
4	Different spindle checkpoint proteins monitor microtubule attachment and tension at kinetochores in Drosophila cells. Journal of Cell Science, 2004, 117, 1757-1771.	2.0	100
5	Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomaterialia, 2017, 47, 71-80.	8.3	94
6	The Human Spindle Assembly Checkpoint Protein Bub3 Is Required for the Establishment of Efficient Kinetochore–Microtubule Attachments. Molecular Biology of the Cell, 2008, 19, 1798-1813.	2.1	86
7	Localization of the Drosophila checkpoint control protein Bub3 to the kinetochore requires Bub1 but not Zw10 or Rod. Chromosoma, 1998, 107, 376-385.	2.2	84
8	Kinetochore-microtubule interactions "in check―by Bub1, Bub3 and BubR1: The dual task of attaching and signalling. Cell Cycle, 2008, 7, 1763-1768.	2.6	70
9	Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint. Cell Proliferation, 2011, 44, 391-400.	5.3	62
10	Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. Cancer Letters, 2019, 440-441, 64-81.	7.2	60
11	<i>Mad2</i> Checkpoint Gene Silencing Using Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles in Non-Small Cell Lung Cancer Model. Molecular Pharmaceutics, 2014, 11, 3515-3527.	4.6	55
12	High <scp>CDC</scp> 20 expression is associated with poor prognosis in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2014, 43, 225-231.	2.7	54
13	Biodistribution and pharmacokinetics of <i>Mad2</i> siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models. Nanomedicine, 2016, 11, 767-781.	3.3	51
14	New chiral derivatives of xanthones: Synthesis and investigation of enantioselectivity as inhibitors of growth of human tumor cell lines. Bioorganic and Medicinal Chemistry, 2014, 22, 1049-1062.	3.0	41
15	Cytotoxic effects of submicron- and nano-scale titanium debris released from dental implants: an integrative review. Clinical Oral Investigations, 2021, 25, 1627-1640.	3.0	39
16	Mad2-independent Spindle Assembly Checkpoint Activation and Controlled Metaphase–Anaphase Transition inDrosophilaS2 Cells. Molecular Biology of the Cell, 2007, 18, 850-863.	2.1	36
17	EMMPRIN Expression in Oral Squamous Cell Carcinomas: Correlation with Tumor Proliferation and Patient Survival. BioMed Research International, 2014, 2014, 1-9.	1.9	36
18	Maternal expression of the checkpoint protein BubR1 is required for synchrony of syncytial nuclear divisions and polar body arrest in Drosophila melanogaster. Development (Cambridge), 2005, 132, 4509-4520.	2.5	34

#	Article	IF	CITATIONS
19	Dynein-dependent transport of spindle assembly checkpoint proteins off kinetochores toward spindle poles. FEBS Letters, 2014, 588, 3265-3273.	2.8	34
20	Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy. Current Drug Targets, 2015, 16, 1448-1463.	2.1	33
21	Chalcone derivatives targeting mitosis: synthesis, evaluation of antitumor activity and lipophilicity. European Journal of Medicinal Chemistry, 2019, 184, 111752.	5.5	32
22	Prognostic significance of CD44v6, p63, podoplanin and MMPâ€9 in oral squamous cell carcinomas. Oral Diseases, 2016, 22, 303-312.	3.0	28
23	Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics, 2021, 13, 1011.	4.5	26
24	Mutational analysis of MSX1 and PAX9 genes in Portuguese families with maxillary lateral incisor agenesis. European Journal of Orthodontics, 2010, 32, 582-588.	2.4	25
25	Targeting the Spindle Assembly Checkpoint for Breast Cancer Treatment. Current Cancer Drug Targets, 2015, 15, 272-281.	1.6	25
26	The spindle assembly checkpoint: perspectives in tumorigenesis and cancer therapy. Frontiers in Biology, 2011, 6, 147-155.	0.7	23
27	Evaluation of 2′,4′-dihydroxy-3,4,5-trimethoxychalcone as antimitotic agent that induces mitotic catastrophe in MCF-7 breast cancer cells. Toxicology Letters, 2014, 229, 393-401.	0.8	23
28	Effects of a Long-standing Challenge on Pulmonary Neuroendocrine Cells of Actively Sensitized Guinea Pigs. The American Review of Respiratory Disease, 1991, 144, 714-717.	2.9	22
29	Screening a Small Library of Xanthones for Antitumor Activity and Identification of a Hit Compound which Induces Apoptosis. Molecules, 2016, 21, 81.	3.8	22
30	Changes in chromogranin A-immunoreactive guinea-pig pulmonary neuroendocrine cells after sensitization and challenge with ovalbumin. Cell and Tissue Research, 1994, 275, 195-199.	2.9	18
31	Combinatorial-Designed Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles for Encapsulation and Delivery of Lipid-Modified Platinum Derivatives in Wild-Type and Resistant Non-Small-Cell Lung Cancer Cells. Molecular Pharmaceutics, 2015, 12, 4466-4477.	4.6	18
32	Spindly and Bub3 expression in oral cancer: Prognostic and therapeutic implications. Oral Diseases, 2019, 25, 1291-1301.	3.0	17
33	Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel. Cancer Letters, 2017, 394, 33-42.	7.2	16
34	Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives. Clinical Colorectal Cancer, 2017, 16, 1-8.	2.3	16
35	New Alkoxy Flavone Derivatives Targeting Caspases: Synthesis and Antitumor Activity Evaluation. Molecules, 2019, 24, 129.	3.8	15
36	Acute response of the arterial wall to pulsed laser irradiation. Lasers in Surgery and Medicine, 1993, 13, 412-420.	2.1	14

#	Article	IF	CITATIONS
37	Clinicopathologic significance of BubR1 and Mad2 overexpression in oral cancer. Oral Diseases, 2015, 21, 713-720.	3.0	14
38	Discovery of a New Xanthone against Glioma: Synthesis and Development of (Pro)liposome Formulations. Molecules, 2019, 24, 409.	3.8	14
39	An Overview of the Spindle Assembly Checkpoint Status in Oral Cancer. BioMed Research International, 2014, 2014, 1-8.	1.9	13
40	Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel. Molecules, 2016, 21, 982.	3.8	12
41	Yicathins B and C and Analogues: Total Synthesis, Lipophilicity and Biological Activities. ChemMedChem, 2020, 15, 749-755.	3.2	12
42	Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic. Scientific Reports, 2021, 11, 4139.	3.3	12
43	Rat diaphragm during postnatal development. I. Changes in distribution of muscle fibre type and in oxidative potential. Reproduction, Fertility and Development, 1996, 8, 391.	0.4	10
44	Synthesis of New Glycosylated Flavonoids with Inhibitory Activity on Cell Growth. Molecules, 2018, 23, 1093.	3.8	9
45	Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein. Frontiers in Oncology, 2021, 11, 752127.	2.8	9
46	Synthesis of New Chiral Derivatives of Xanthones with Enantioselective Effect on Tumor Cell Growth and DNA Crosslinking. ChemistrySelect, 2020, 5, 10285-10291.	1.5	8
47	Novel Anticancer Strategies. Pharmaceutics, 2021, 13, 275.	4.5	8
48	BP-M345, a New Diarylpentanoid with Promising Antimitotic Activity. Molecules, 2021, 26, 7139.	3.8	8
49	Chiral derivatives of xanthones and benzophenones: Synthesis, enantioseparation, molecular docking, and tumor cell growth inhibition studies. Chirality, 2021, 33, 153-166.	2.6	7
50	BUB3, beyond the Simple Role of Partner. Pharmaceutics, 2022, 14, 1084.	4.5	7
51	Coâ€silencing of human Bub3 and dynein highlights an antagonistic relationship in regulating kinetochore–microtubule attachments. FEBS Letters, 2015, 589, 3588-3594.	2.8	6
52	A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel. Molecules, 2020, 25, 5845.	3.8	6
53	Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. Pharmaceutics, 2022, 14, 1209.	4.5	3
54	Tetracyclic Thioxanthene Derivatives: Studies on Fluorescence and Antitumor Activity. Molecules, 2021, 26, 3315.	3.8	2

#	Article	IF	CITATIONS
55	The Mad2-Binding Protein p31comet as a potential target for human cancer therapy. Current Cancer Drug Targets, 2021, 21, 401-415.	1.6	1
56	<title>Restenosis after pulsed laser irradiation</title> ., 1993, 1878, 145.		0
57	The Kinetochore and Mitosis: Focus on the Regulation and Correction Mechanisms of Chromosome-to-Microtubule Attachments., 0,,.		O
58	Antimitotic Drugs. , 2014, , 1-2.		0